NICE Recommends Abaloparatide for Osteoporosis in the Elderly

By Staff Writer

September 10, 2024

Introduction

The National Institute for Health and Care Excellence (NICE) has recently recommended abaloparatide for treating osteoporosis in postmenopausal women, trans men, and non-binary individuals at very high risk of fracture. This guidance is essential for healthcare in the elderly, aiming to improve bone health and reduce fracture risk.

Understanding Osteoporosis and Its Impact

Osteoporosis is a progressive skeletal disorder characterised by low bone density, leading to an increased risk of fractures. These fractures can be painful and significantly affect a person’s independence and quality of life. According to patient experts, the fear of fractures often leads to anxiety and withdrawal from daily activities. Consequently, managing osteoporosis effectively is crucial for enhancing the well-being of the elderly.

Current Treatment Landscape

Traditional treatments for osteoporosis include bisphosphonates like alendronic acid, and anabolic treatments such as teriparatide and romosozumab. These treatments aim to improve bone strength and reduce fracture risk. However, they have limitations, including side effects like hypercalcaemia and osteonecrosis, which can affect adherence. For instance, teriparatide requires refrigeration, posing a challenge for those who travel frequently.

The Role of Abaloparatide

Abaloparatide is a newer anabolic treatment option. It has shown to be effective in reducing the risk of vertebral fractures by 88% compared to placebo, according to the ACTIVE trial. This treatment is recommended for those at very high risk of fractures, defined by a 60% higher fracture probability than the intervention threshold. Unlike teriparatide, abaloparatide does not require refrigeration after the first use, making it more convenient for patients.

Clinical and Economic Considerations

Clinical trials and real-world evidence support the efficacy of abaloparatide. The ACTIVE trial demonstrated a significant reduction in fracture risk, while a real-world study showed that abaloparatide was statistically non-inferior to teriparatide for non-vertebral fractures. Economically, abaloparatide’s cost-effectiveness falls within the acceptable range for NHS resources, with a list price of £294.54 per pre-filled pen.

Cost Effectiveness Analysis

NICE’s evaluation of abaloparatide’s cost-effectiveness considered incremental cost-effectiveness ratios (ICERs) and quality-adjusted life years (QALYs). The analysis highlighted that incremental QALYs were small, causing ICERs to fluctuate significantly. Therefore, net health benefit was used as a more stable measure. Abaloparatide’s net health benefit, at a threshold value of £20,000 per QALY gained, was compared with that of romosozumab and teriparatide. This approach confirmed that abaloparatide is a cost-effective option for the NHS, providing a viable and economically sound treatment for those at very high risk of fractures.

Conclusion

NICE’s recommendation of abaloparatide offers a promising alternative for managing osteoporosis in elderly patients at very high risk of fractures. This guidance not only addresses the clinical needs but also considers the economic implications, ensuring a balanced approach to healthcare delivery.

Reference url

Recent Posts

Enhertu reimbursement analysis
                 

Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

💡 How do we balance groundbreaking cancer treatments with budget realities?

The recent analysis by the Dutch Healthcare Institute on Enhertu shines a light on the complexities of integrating innovative therapies for HER2-low metastatic breast cancer into national insurance packages. While the clinical efficacy is evident, the substantial cost implications and demand for steep price reductions bring significant challenges to market access.

Explore the nuances of this vital discussion on clinical effectiveness, economic evaluation, and the future of pricing strategies in oncology.

#SyenzaNews #HealthEconomics #MarketAccess

drug price comparison
 

Global Drug Price Gaps Demand Better Drug Pricing Analysis

💊 International drug price comparison reveal stark price gaps—the U.S. pays 4.2 times more for brand-name drugs than OECD peers.

But are these studies fueling a market collapse or opening a strategic opportunity for sustainable pricing in the U.S. and globally?

Discover the shortcomings of international pricing comparisons and how robust drug pricing analysis can help balance access, affordability, and profitability in a complex market.

#SyenzaNews #healthcare #pricing

NICE HealthTech Reforms
            

NICE HealthTech Reforms: Accelerating Digital Innovation in NHS and Global Healthcare Systems

🌐 Are you ready to witness a paradigm shift in digital health technology?

The National Institute for Health and Care Excellence (NICE) has announced transformative reforms aimed at accelerating the adoption of digital health innovations within the NHS. By focusing on cost-effectiveness rather than mere cost savings, these changes promise to streamline regulatory processes and enhance evaluations aligned with healthcare priorities.

Dive into this insightful article to explore how NICE’s reforms could reshape the future of healthcare systems globally!

#SyenzaNews #DigitalHealth #HealthEconomics #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.